Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dabrafenib monotherapy for a recurrent BRAFV600E-mutated TTF-1-positive posterior pituitary tumor.

Acta neurochirurgica - 1 Mar 2022

Grenier-Chartrand Flavie, Barrit Sami, Racu Marie Lucie, Luce Sylvie, Spitaels Julien, Sadeghi-Meibodi Niloufar, Lebrun Laetitia, Salmon Isabelle, Lefranc Florence, De Witte Olivier

Abstract excerpt

Posterior pituitary tumors (PPT) expressing thyroid transcription factor-1 (TTF-1) are extremely rare low-grade neoplasms. The recent discovery of BRAF mutations in these tumors offers a potential alternative treatment using targeted therapies. We present the case of a 57-year-old female with recurrent BRAFV600E-mutated TTF-1-positive PPT treated with a BRAF inhibitor monotherapy (dabrafenib) leading to tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Imidazoles
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oximes

Share to Pituitary Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Nuclear Factor 1

Source

Identifiers

PMID: 35029761
DOI: 10.1007/s00701-022-05109-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dabrafenib monotherapy for a recurrent BRAFV600E-mutated TTF-1-positive posterior pituitary tumor.PMID 35029761Read ↗

TTF-1 positive posterior pituitary tumor: Limitations of current treatment and potential new hope in BRAF V600E mutation variants.Semantic proximity Read ↗

Molecular therapy for papillary craniopharyngioma: a multi-institutional analysis of practice patterns across the RAPID Consortium.Semantic proximity Read ↗

Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial.Semantic proximity Read ↗

A single-center retrospective study of dabrafenib plus trametinib combination therapy in patients with BRAF V600E-positive thyroid cancerSemantic proximity Read ↗

Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.Semantic proximity Read ↗

BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series.Semantic proximity Read ↗

BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.Semantic proximity Read ↗

Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600E-Mutated Thyroid Cancer.Semantic proximity Read ↗

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.Semantic proximity Read ↗

A Rare Case of Pituitary Melanoma Metastasis: A Dramatic and Prolonged Response to Dabrafenib-Trametinib Therapy.Semantic proximity Read ↗

Successful Use of BRAF/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma.Semantic proximity Read ↗

Dabrafenib as a diagnostic and therapeutic strategy for the non-surgical management of papillary craniopharyngioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.